CONTACT US
Home > Inhibitors/Agonists> > Ivabradine hemisulfate
1422274-66-5-Ivabradine hemisulfate Ivabradine hemisulfate

Ivabradine hemisulfate

For research use only. Not for therapeutic Use.

  • CAT Number: I029673
  • CAS Number: 1422274-66-5
  • Molecular Formula: C54H74N4O14S
  • Molecular Weight: 1035.26
  • Purity: 98%
Inquiry Now
Related Small Molecules: SM-360320     LOXO-195 R-isomer     Iristectorin B    

Ivabradine hemisulfate is a novel biochemical for symptomatic management of stable angina pectoris.


Catalog Number I029673
CAS Number 1422274-66-5
Synonyms

Ivabradine hemisulfate

Molecular Formula C54H74N4O14S
Purity 98%
Solubility To be determined
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, sulfate (2:1)
InChI InChI=1S/2C27H36N2O5.H2O4S/c2*1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;1-5(2,3)4/h2*12-14,16,21H,6-11,15,17H2,1-5H3;(H2,1,2,3,4)/t2*21-;/m11./s1
InChIKey AMRKLKWJQKOGOF-ITEXDBGESA-N
SMILES COc1cc2CCN(CCCN(C)C[C@H]3Cc4cc(OC)c(OC)cc34)C(=O)Cc2cc1OC.COc5cc6CCN(CCCN(C)C[C@H]7Cc8cc(OC)c(OC)cc78)C(=O)Cc6cc5OC.OS(=O)(=O)O
Reference

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548107/ PubMed PMID: 31643437.
2: Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, Huang J. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clin Ther. 2019 Oct;41(10):2137-2152.e12. doi: 10.1016/j.clinthera.2019.08.008. Epub 2019 Sep 21. Review. PubMed PMID: 31548105.
3: Mayhew A, Loshak H. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 15. Available from http://www.ncbi.nlm.nih.gov/books/NBK545894/ PubMed PMID: 31487130.
4: Zhou Y, Wang J, Meng Z, Zhou S, Peng J, Chen S, Wang Q, Sun K. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure. Curr Top Med Chem. 2019;19(21):1878-1901. doi: 10.2174/1568026619666190809093144. Review. PubMed PMID: 31400267.
5: Sattar Y, Neisani Samani E, Zafrullah F, Latchana S, Patel NB. Ivabradine in Congestive Heart Failure: Patient Selection and Perspectives. Cureus. 2019 Apr 13;11(4):e4448. doi: 10.7759/cureus.4448. Review. PubMed PMID: 31205834; PubMed Central PMCID: PMC6561528.
6: Katsi V, Skalis G, Kallistratos MS, Tsioufis K, Makris T, Manolis AJ, Tousoulis D. Ivabradine and metoprolol in fixed dose combination: When, why and how to use it. Pharmacol Res. 2019 Aug;146:104279. doi: 10.1016/j.phrs.2019.104279. Epub 2019 May 17. Review. PubMed PMID: 31108185.
7: Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. Review. PubMed PMID: 31074301.
8: Sathyamurthy I, Newale S. Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian Heart J. 2018 Dec;70 Suppl 3:S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20. Review. PubMed PMID: 30595304; PubMed Central PMCID: PMC6309574.
9: CADTH Canadian Drug Expert Committee Recommendation: Ivabradine Hydrochloride (Lancora — Servier Canada Inc.): Indication: Heart Failure, NYHA class II to III [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 24. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533855/ PubMed PMID: 30462447.
10: Pharmacoeconomic Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533848/ PubMed PMID: 30462445.
11: Patient Group Input Submissions: Ivabradine (Lancora) for Heart failure, NYHA class II to IV [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533856/ PubMed PMID: 30462443.
12: Clinical Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533838/ PubMed PMID: 30462437.
13: Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis. 2018 Jul 4;9(11):199-207. doi: 10.1177/2040622318784556. eCollection 2018 Nov. Review. PubMed PMID: 30364460; PubMed Central PMCID: PMC6196638.
14: Dodd K, Lampert BC. The Use and Indication of Ivabradine in Heart Failure. Heart Fail Clin. 2018 Oct;14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18. Review. PubMed PMID: 30266358.
15: Reed M, Nicolas D. Ivabradine. 2019 Oct 8. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507783/ PubMed PMID: 29939560.
16: Chow SL, Page RL 2nd, Depre C. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. Expert Rev Cardiovasc Ther. 2018 Jul;16(7):515-526. doi: 10.1080/14779072.2018.1489235. Epub 2018 Jul 2. Review. PubMed PMID: 29902387.
17: Kaski JC, Gloekler S, Ferrari R, Fox K, Lévy BI, Komajda M, Vardas P, Camici PG. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart. 2018 Mar 9;5(1):e000725. doi: 10.1136/openhrt-2017-000725. eCollection 2018. Review. PubMed PMID: 29632676; PubMed Central PMCID: PMC5888443.
18: Gee ME, Watkins AK, Brown JN, Young EJA. Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review. Am J Cardiovasc Drugs. 2018 Jun;18(3):195-204. doi: 10.1007/s40256-017-0252-1. Review. PubMed PMID: 29330767.
19: Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2018 Feb;15(2):240-247. doi: 10.1016/j.hrthm.2017.10.004. Epub 2017 Oct 7. Review. PubMed PMID: 29017929.
20: Kang S, Li CJ, Zhang XM. Ivabradine has a neutral effect on mortality in randomized controlled trials. Medicine (Baltimore). 2017 Oct;96(40):e8067. doi: 10.1097/MD.0000000000008067. Review. PubMed PMID: 28984762; PubMed Central PMCID: PMC5737998.

Request a Quote